Freenome announced Tuesday the launch of its new Sanderson study, which will use its multi-omics platform, combining real-world data, some from Oracle Cerner’s Learning Health Network, to improve detection and treatment several types of cancer.
Why is it important
San Francisco-based Freenome’s multi-omics platform can use standard blood draws to detect cancer earlier. The company focuses on advanced computational biology, using machine learning to detect patterns in billions of circulating cell-free biomarkers.
The study will use traditional and real-world data to generate evidence for clinical validation in certain high-risk and high-risk populations, while also improving the platform’s oncology, Freenome said Classification and risk prediction models.
The goal of the Sanderson study is to build infrastructure that, according to Freenome, can bridge the gap between clinical research and day-to-day clinical impact. risk. Freenome’s multi-omics platform combines tumor and non-tumor signaling with machine learning to detect early stages of cancer.
Freenome clinical study named after loved one of employee battling cancer; Sanderson study tribute to Tim Sanderson, father of Freenome engineer. It will enroll approximately 8,000 patients through Freenome’s network of clinical research partners and numerous regional health systems in the United States.
It will focus on cancers with significant unmet needs, such as pancreatic and lung cancers.
Oracle Cerner’s Learning Health Network – made up of 90 different health systems across the country providing de-identified clinical trial data – will be a key partner.
Additionally, the company said Elligo Health Research will work with LHN members to use existing health data to identify and recruit patients significantly faster than traditional recruitment models.
Cerner first announced a collaboration with Elligo this May, Freenome in Sanderson Research. “Our long-term goal is to advance multi-cancer products into clinical practice to save more lives,” Freenome co-founder Riley Ennis said at the time.
The Cerner Institute, in collaboration with Duke Clinical, launched the Learning Health Network in 2019 with the goal of automatically collecting data from multiple sources, including electronic health records.
Designed to enable clinicians to gain health insights and guide care more easily and effectively, to give medical researchers faster and easier access to data, and to help them innovate new approaches to health .
In October 2021, the company announced the creation of Cerner Enviza, an operating unit focused on developing new approaches to data management for life science research and the development of new treatments and therapies.
“Earlier cancer detection and more convenient screening will expand Bett’s available treatments,” said Christy Dueck, vice president of Cerner Enviza. “Oracle Cerner is pleased to partner with Freenome to help speed up the research process, from hospital and health system readiness to Patient engagement and identification. The Learning Health Network facilitates by addressing the current challenges of scarcity of traditional websites. Model clinical trials by creating large numbers of patients who are already actively participating in healthcare. “
“We are combining real-world data with a precision health mindset for clinical actionability,” Freenome Chief Medical Officer Dr. Lance Baldo said in a statement. Our goal is to identify the right patient for the right screening test at the right time, with clear next steps. We believe this approach will ultimately save more lives. “
Email the author: [email protected] .com
Healthcare IT News is a HIMSS publication.